Among patients with RSTS, roughly 50–60% harbor pathogenic variants in CREBBP (RSTS type I), while only 3–8% of the patients harbor mutations in EP300 (RSTS type II) (López et al., 2018). This evidence concerns the gene EP300 and Rubinstein-Taybi syndrome.